BioPlus Acquisition Corp

BioPlus Acquisition — SPAC Merger (May 2023)

43 slides from BioPlus Acquisition's SPAC merger presentation, May 3, 2023

  1. Slide 1: Investor Presentation May 2023

    Exhibit 99.2 Investor Presentation May 2023

  2. Slide 2: Disclaimers (1 of 2)

    Disclaimers (1 of 2) This presentation and any accompanying oral presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Avertix Medical,

  3. Slide 3: Disclaimers (2 of 2)

    Disclaimers (2 of 2) Use of Data The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein

  4. Slide 4: Summary of Risk Factors (1 of 2)

    Summary of Risk Factors (1 of 2) Risks Related to Avertix’s Business • Avertix has a history of operating losses and may not achieve or sustain profitability in the future. We expect to incur losses for the foreseeable future, and our ability to achieve and maintain profitability depends on the comm

  5. Slide 5: Summary of Risk Factors (2 of 2)

    Summary of Risk Factors (2 of 2) • Enforcement of federal and state laws regarding privacy and security of patient information may adversely affect Avertix’s business, financial condition or operations. • Avertix is subject to data privacy laws that govern the collection, use, disclosure and protect

  6. Slide 6: Summary Transaction Overview

    Summary Transaction Overview ◼ Avertix Medical, Inc. (“Avertix”) and BioPlus Acquisition Corp., (“BIOS”) (NASDAQ: BIOS) to combine to create a publicly listed (1) company with an up to ~$195mm enterprise value Transaction ◼ Post-closing entity expected to be listed on NASDAQ under new ticker, AVRT,

  7. Slide 7: BIOS Investment Criteria

    BIOS Investment Criteria (1) Focused on US, EU, Israel and Australasia Geography Significant Market Company targets a large TAM with unmet needs Opportunity Strong Proven healthcare expertise with public company readiness Management Team Step Changes in Multiple product launches (or other catalysts)

  8. Slide 8: Avertix Presents a Compelling Investment Opportunity

    Avertix Presents a Compelling Investment Opportunity (1) Large addressable market >$2bn annually in US alone Significant TAM (2) Clear white space with limited competition FDA Approved with Broad FDA Approved Class III Cardiac Device with broad label indications Indication Strong IP protection with

  9. Slide 9: Today's Speakers

    Today’s Speakers 1 Ross Haghighat Tim Moran Philip Tom Peter Elia CEO, CFO President, Chief Executive Officer EVP, Chief Financial Officer Chief Revenue Officer BIOS Acquisition Corp. Avertix Avertix Avertix 1) Ross Haghighat (BIOS CEO and CFO, and Avertix’s Executive Chair) has recused himself from

  10. Slide 10: BIOS Board: World Class Biotech Executives

    BIOS Board: World Class Biotech Executives with Synergistic & Complementary Skillsets Ross Jonathan Ronald 1 Haghighat Rigby Eastman Chairman, CBO Vice Chairman CEO, CFO • Chairman & CEO, Triton Systems• CEO, Revolo Biotherapeutics• Senior Advisor, EW Healthcare Partners • Co-Founder, CoreTek Inc.•

  11. Slide 11: Transaction Summary Overview

    Transaction Summary 1 Overview Post-Transaction Ownership BIOS Founder & Private ▪ Fully diluted distributed pro forma enterprise value of up Placement Shares 1 to $195mm , representing 2.6x CY25E revenue Existing Avertix 11.1% Shareholders ▪ Targeting to raise $50mm in PIPE proceeds 28.5% PIPE Inve

  12. Slide 12: Avertix Executive Leadership

    Avertix Executive Leadership Tim Moran Philip Tom Peter Elia President, EVP and Chief Chief Revenue Chief Executive Officer Financial Officer Officer • CEO, Motus GI Holdings (Nasdaq: MOTS)• Former Principal, Explorer (Serial SPAC Sponsor)• Former Chief Strategy and Business • Former President, Conv

  13. Slide 13: It's About Time

    It’s About Time 1 Every 2.6 minutes a heart attack survivor in the US is experiencing a second event. The Guardian is the first and only Class III FDA-approved early 2,3 heart attack warning system. 1) https://www.survivorshaveheart.com/statistics-and-risk.html 2) https://clinicaltrials.gov/ct2/resu

  14. Slide 14: Before The Guardian: Fear and Anxiety of Another Heart Attack

    Before The Guardian: Fear and Anxiety of Another Heart Attack An estimated 8.8 million existing heart attack survivors in the US 1 who ask: Will I have another heart attack? What we offer: Peace of mind 1) https://www.survivorshaveheart.com/statistics-and-risk.html 14

  15. Slide 15: Before The Guardian: Fear and Anxiety of Another Heart Attack

    Before The Guardian: Fear and Anxiety of Another Heart Attack Quality of life can be negatively There’s reason for them to be fearful: affected What’s worse, ~25% In the past, these patients modified their lifestyles, refraining from of heart attack ~1 in 5 exercise, intimacy, and other activities s

  16. Slide 16: Today: The Guardian Provides Peace of Mind & Better Decisions, Faster

    Today: The Guardian Provides Peace of Mind & Better Decisions, Faster Guardian is a silver dollar-sized implantable 1 device that serves as a continuous monitor Now, thanks to Avertix’s Guardian System, the first and only FDA- approved cardiac monitoring and alerting platform designed for the early

  17. Slide 17: The Guardian: A New Paradigm in Cardiac Care

    The Guardian: A New Paradigm in Cardiac Care 24/7/365 Continuous Better decisions, Patented, First-and-only FDA monitoring and proprietary faster: improved approved, CMS- analysis of the algorithm, driven time-to-door for the reimbursed cardiac patients’ unique by machine patient; more monitoring an

  18. Slide 18: How We Got Here

    How We Got Here AngelMed Proprietary Aurora DEVELOPMENT 2001 - 2021 Founded Algorithm Creation Patents Guardian FDA Approval Guardian FDA Approval ALERTS Trial 6yr Implant Life 3yr Implant Life (10 Years) FDA APPROVALS Q3 2021 Q2 2018 Jan 2022 Q1 2022 Q4 2022 Q1 2023 COMMERCIALIZATION Awarded CMS 1s

  19. Slide 19: Avertix Presents a De-Risked Commercial Opportunity

    We Believe Avertix Presents a De-Risked Commercial Opportunity De-Risked Foundation Compelling Commercial Opportunity 1 • FDA Approved Class III Cardiac Device• Large Addressable Market >$2B US • Broad Label Indication• Robust Sales Strategy Projecting $75M Rev in ‘25 • Reimbursement Coverage• Healt

  20. Slide 20: Sizeable US TAM with Significant Whitespace

    Sizeable US TAM with Significant Whitespace Annual Market Opportunity Exceeds Market Size US vs. Outside US (“OUS”) $2 Billion in the US 1 • 8.8M existing heart attack survivors in US • Each year, >800,000 heart attacks, of which 2 >600,000 are new US OUS • All survivors deemed “high risk” • ~25% de

  21. Slide 21: Potential for Rapid Revenue Growth

    Potential for Rapid Revenue Growth Management Projections • US sales expected to ramp to $50M in 2025 Figures in USD millions $75 • Expected nationwide sales coverage, 200+ accounts (Ambulatory Surgery Centers and Hospitals), increasing adoption & $25 productivity • Projections assume implant revenu

  22. Slide 22: The Solution

    The Solution 22

  23. Slide 23: The Solution

    The Solution SOFTWARE HARDWARE Implantable Histogram Derive REAL-TIME • Simple implantation and programming Generation Thresholds ACS • Primary alerting via vibration DETECTION Intracardiac Lead Wireless Signal (1.80m) External Receiver Machine Learning • Secondary audio/visual alerting Subcutaneous

  24. Slide 24: Proven Impact and Benefits of Guardian

    Proven Impact and Benefits of Guardian Until Now - Patients with Ejection Fraction (“EF”) >35, Post-Myocardial Infarction (“MI”) Don’t Have A Diagnostics (“Dx”) Solution Alert System Physician assesses patient’s “See Doctor” Alert Higher non-urgent condition LVEF Post- MI “Call 911 / Emergency” Aler

  25. Slide 25: The Avertix Platform

    The Avertix Platform Hardware Software Revenue Streams Implant (TPT) Physician Visits Aurora Remote Patient Monitoring Algorithm Data Capture and Monetization Simpler Form Factor / Easier Adoptability Diagnostics MI Detection Custom Treatment Plans and Use Cases (“Dx”) (Symptomatic and Silent) Compl

  26. Slide 26: ALERTS Clinical Study Key Findings: Time-to-Door

    ALERTS Clinical Study Key Findings: 100 Centers n=907 Impact on Time-to-Door for Heart Attacks Other Clinical Findings Symptom + alarm was 40+ 26% 91% Silent MI’s detected Reduction in more predictive than 2 2 (~20% of total) unnecessary ER visits symptoms alone for 2 real ACS event REDUCES Detected

  27. Slide 27: ALERTS Clinical Study Key Findings: Quality-of-Life

    ALERTS Clinical Study Key Findings 1 Impact on Quality-of-Life 1) ALERTS Quality-Of-Life (AQOL) Sub-study (Company Study); https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150009C.pdf 27

  28. Slide 28: Our Positioning Focuses on the Unprotected Patient: EF>35

    Our Positioning Focuses on the Unprotected Patient: EF>35 “Ejection Fraction (EF) is a measurement that your physician may use to gauge how healthy your heart is. Your ejection fraction is the amount of blood that your heart pumps each time it beats.” – University of Pennsylvania Medicine EF: 35% or

  29. Slide 29: Commercial Strategy

    Commercial Strategy 29

  30. Slide 30: Proven Commercial Leadership Extending Reach and Talent

    Proven Commercial Leadership Extending Reach and Talent Sales Team Operational Leadership Sales Team Footprint End of 2022 Mike Gillem • Former CCO, McGinley Orthopedics, • Previously leadership roles at Foxhollow Technologies, Cayenne Medical Arin Barooah =District Sales Manager (5) • Former CRO, V

  31. Slide 31: Commercial Playbook: Network Referral & Scalable Execution Model

    Commercial Playbook: Network Referral & Scalable Execution Model Hospital and ASC Referrals Physician to Physician Referral One designated “Implanter” likely an Electrophysiologist who has expertise in Pacemakers, Implantable Cardiac Defibrillators (ICDs), etc. in the practice. Commercial Strategy •

  32. Slide 32: Ambulatory Surgery Centers (ASCs): A Key Focus

    Ambulatory Surgery Centers (ASCs): A Key Focus 1 2 ASC Reimbursement Dynamics % of Cardiology Procedures Performed in ASCs ASC Specific APC Payment (0525T) Total $6,266 33% Device Offset Amount -$2,903 Net APC Payment $3,659 10% Transitional Pass-Through Payment to Avertix (C1833) $10,250 4% Estimat

  33. Slide 33: Building Significant Hospital Presence w/ High Value Analysis Committee Approval

    Building Significant Hospital Presence w/ High Value Analysis Committee Approval Success Rate 1 Hospital Reimbursement Dynamics Sample Partner Hospitals Where Guardian is Approved Hospital Specific APC Payment (0525T) Total $10,329 Device Offset Amount -$8,246 Net APC Payment $2,083 Transitional Pas

  34. Slide 34: Case Studies from the Field

    1 Case Studies from the Field Early Ischemic Heart Detection with Early Arrythmia Detection Guardian ST Trending See Dr.Alert July 8th 9 December ST Deviation Trending Asymptomatic Asymptomatic patients Threshold patients diagnosed with (Max-Min >20) diagnosed Guardian Arrythmia with ST event storag

  35. Slide 35: Building a Global Business

    Building a Global Business International Strategy Partnership Activity Approval Status OUS • Avertix entered a Distribution and Supply Agreement with Hydrix in 2020 Singapore Applications Malaysia • Avertix entered a Product Distribution Agreement in MENA Approved Thailand in 2023 New Zealand • Earl

  36. Slide 36: Technology Roadmap

    Technology Roadmap 36

  37. Slide 37: The Avertix Platform

    The Avertix Platform Hardware Software Revenue Streams Implant (TPT) Physician Visits Aurora Remote Patient Monitoring Algorithm Data Capture and Monetization Simpler Form Factor / Easier Adoptability MI Detection Custom Treatment Plans and Use Cases Diagnostics (Symptomatic and Silent) Compliance 3

  38. Slide 38: The Avertix Platform Expansion

    The Avertix Platform Expansion Hardware Software Revenue Streams Implant (TPT) Physician Visits Aurora Remote Patient Monitoring Algorithm Data Capture and Monetization Simpler Form Factor / Easier Adoptability MI Detection Custom Treatment Plans and Use Cases Diagnostics (Symptomatic and Silent) Co

  39. Slide 39: Completed and Expected Upcoming Key Milestones

    Completed and Expected Upcoming Key Milestones FY ‘23 FY ‘24 $85M MENA Agreement Aurora FDA Submission Q1 H1 Sales Force Expansion & EU MDR Submission Q1+ H1 Revenue Ramp Next GEN Aurora Design Freeze EU MDR Approval Q2 H2 Q4 MENA Regulatory Approval Next GEN Aurora FDA Approval H2 39

  40. Slide 40: Financial Profile

    Financial Profile 40

  41. Slide 41: Potential for Rapid Revenue Growth

    Potential for Rapid Revenue Growth Management Projections • US sales expected to ramp to $50M in 2025 Figures in USD millions $75 • Expected nationwide sales coverage, 200+ accounts (ASCs and Hospitals), increasing adoption & productivity $25 • Projections assume implant revenue of reimbursable $10,

  42. Slide 42: Avertix Revenue Streams: Significant Opportunities for Growth

    Avertix Revenue Streams: Significant Opportunities for Growth Implant Physician Patient Other Visits Subscription TPT code Remote patient Remote patient Data, reporting, monitoring: monitoring with analytics Wound check, 14 day customizable and 3, 6, 12-month notifications check-ups; alert-driven ap

  43. Slide 43: Avertix Presents a De-Risked Commercial Opportunity

    We Believe Avertix Presents a De-Risked Commercial Opportunity De-Risked Foundation Compelling Commercial Opportunity 1 • FDA Approved Class III Cardiac Device• Large Addressable Market >$2B US • Broad Label Indication• Robust Sales Strategy Projecting $75M Rev in ‘25 • Reimbursement Coverage• Healt

BioPlus Acquisition — SPAC Merger (May 2023) on 6ix